Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas

Acinar cell carcinoma of the pancreas is a rare malignancy representing less than 1% of all pancreatic malignancies. We report on a case series of 21 patients with acinar cell carcinoma of the pancreas treated at a high-volume quaternary center. A systematic review of the medical literature was perf...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer control Vol. 23; no. 4; p. 446
Main Authors:	Glazer, Evan S, Neill, Kevin G, Frakes, Jessica M, Coppola, Domenico, Hodul, Pamela J, Hoffe, Sara E, Pimiento, Jose M, Springett, Gregory M, Malafa, Mokenge P
Format:	Journal Article
Language:	English
Published:	United States 01-10-2016
Subjects:	Carcinoma, Acinar Cell - pathology Female Humans Male Middle Aged Pancreatic Neoplasms - pathology
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Acinar cell carcinoma of the pancreas is a rare malignancy representing less than 1% of all pancreatic malignancies. We report on a case series of 21 patients with acinar cell carcinoma of the pancreas treated at a high-volume quaternary center. A systematic review of the medical literature was performed that described typical therapeutic management approaches for acinar cell carcinoma of the pancreas and reported on disease control and survival rates. Data for the case series were obtained from a prospective database. In our systematic review of 6 articles, study patients had a median age of 61 years, 66% were male, 52% had stage I/II disease, and 55% of lesions were located in the pancreatic head. The rates of median survival were approximately 47 months after resection with adjuvant therapy, 38 months for nonmetastatic, locally unresectable disease, and 17 months for metastatic disease treated with chemotherapy. Combination fluoropyrimidine-based chemotherapy regimens had better rates of disease control than other therapies. Our case series included 21 study patients, 14 of whom required resection and 7 who had metastatic disease. The rates of median survival were 40.2 ± 31.9 months in those who underwent surgery and were treated with adjuvant therapy and 13.8 ± 11.3 months for patients with metastatic disease. Multidisciplinary treatment for acinar cell carcinoma of the pancreas should be considered due to the rarity of the disease and its lack of high-level therapeutic data. Progress in the molecular analysis of this tumor may improve outcomes through the use of personalized therapy based on underlying tumor mutations.
ISSN:	1526-2359
DOI:	10.1177/107327481602300417